Publication Name	World Journal of Gastroenterology
Manuscript ID	8614
Country	China

Received	2013-12-31 11:49
Peer-Review Started	2013-12-31 19:29
To Make the First Decision	2014-02-14 18:05
Return for Revision	2014-02-18 20:59
Revised	2014-03-30 10:27
Second Decision	2014-05-05 09:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-05-05 09:59
Articles in Press	2014-05-23 09:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-02 16:42
Publish the Manuscript Online	2014-07-21 17:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Topic Highlights
Article Title	Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Ye Liu, Rui Wei and Tian-Pei Hong
Funding Agency and Grant Number	Funding Agency Grant Number Research Fund for the Doctoral Program of Higher Education of China 20120001120069 National Basic Research Program of China (973 Program) 2012CB517502
Corresponding Author	Tian-Pei Hong, MD, PhD, Chief, Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, China. tpho66@bjmu.edu.cn
Key Words	Non-alcoholic fatty liver disease; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Insulin resistance; Oxidative stress; Lipid metabolism
Core Tip	Recently, an association of defective glucagon-like peptide-1 (GLP-1) signalling with non-alcoholic fatty liver disease (NAFLD) has been documented. GLP-1-based therapies, which are well accepted in treating diabetes, are effective in improving hepatic endpoints in NAFLD. In addition to the benefits in controlling metabolic disorders, GLP-1-based agents may directly exert actions on the liver through activation of GLP-1 receptors in hepatocytes, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells. Therefore, GLP-1-based therapies may have potential roles in treating NAFLD.
Publish Date	2014-07-21 17:17
Citation	Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9090-9097
URL	http://www.wjgnet.com/1007-9327/full/v20/i27/9090.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i27.9090

Full Article (PDF)	WJG-20-9090.pdf
Full Article (Word)	WJG-20-9090.doc
Manuscript File	8614-Review.doc
Answering Reviewers	8614-Answering reviewers.pdf
Copyright License Agreement	8614-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	8614-Language certificate.pdf
Peer-review Report	8614-Peer review.pdf
Scientific Editor Work List	8614-Scientific editor work list.pdf